Bristol-Myers Squibb Company Stock Analysis & AI Score
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NYSE |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
Bristol-Myers Squibb Company (BMY) holds an ST Score of 64.1 out of 100 (B), with its strongest factor being Sentiment (A+) and its weakest Financial Strength (C). Analysts rate BMY Buy across 42 ratings with a $70.00 average price target (+0.1% vs the current $62.62).
- Strongest
- SentimentA+
- Weakest
- Financial StrengthC
All factor grades
- SentimentA+
- ProfitabilityB+
- MomentumB
- ForecastB
- GrowthB-
- ValuationC
- Financial StrengthC
- Piotroski7/9
Contact
BMY stock: frequently asked questions
What is BMY's ST Score?
Bristol-Myers Squibb Company (BMY) has an ST Score of 64.1 out of 100, an overall grade of B. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is BMY a buy, sell, or hold?
Wall Street's consensus rating on BMY is Buy based on 42 analyst ratings. Our own ST Score grades it B (64.1/100). This is data, not investment advice — always do your own research.
What is BMY's valuation grade?
Bristol-Myers Squibb Company (BMY) earns a valuation grade of C, measured against Drug Manufacturers - General peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is BMY's growth grade?
Bristol-Myers Squibb Company (BMY) earns a growth grade of B-, measured against Drug Manufacturers - General peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is BMY's profitability grade?
Bristol-Myers Squibb Company (BMY) earns a profitability grade of B+, measured against Drug Manufacturers - General peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is BMY's financial strength grade?
Bristol-Myers Squibb Company (BMY) earns a financial strength grade of C, measured against Drug Manufacturers - General peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for BMY?
The average analyst price target for Bristol-Myers Squibb Company (BMY) is $70.00 from 42 analysts, which is +0.1% versus the recent price of $62.62.
What is BMY's Piotroski score?
Bristol-Myers Squibb Company (BMY) has a Piotroski F-Score of 7 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.